[go: up one dir, main page]

WO2002033103A3 - Non-human mammal with modified pacap type i receptor - Google Patents

Non-human mammal with modified pacap type i receptor Download PDF

Info

Publication number
WO2002033103A3
WO2002033103A3 PCT/DE2001/003957 DE0103957W WO0233103A3 WO 2002033103 A3 WO2002033103 A3 WO 2002033103A3 DE 0103957 W DE0103957 W DE 0103957W WO 0233103 A3 WO0233103 A3 WO 0233103A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
modified
human mammal
pacap type
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2001/003957
Other languages
German (de)
French (fr)
Other versions
WO2002033103A2 (en
Inventor
Christiane Otto
Guenther Schuetz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Publication of WO2002033103A2 publication Critical patent/WO2002033103A2/en
Publication of WO2002033103A3 publication Critical patent/WO2002033103A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A non-human mammal is disclosed with a modified, preferably inactivated PACAP type I receptor (PAC1). The invention further relates to production of such a mammal and the use thereof for the characterisation of genes and/or testing of substances, medicaments, and therapeutic formulations with regard to disease states such as, for example, visceral pain conditions, learning difficulties, anxiety states or dilatative cardiomyopathy.
PCT/DE2001/003957 2000-10-16 2001-10-16 Non-human mammal with modified pacap type i receptor Ceased WO2002033103A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10051259.3 2000-10-16
DE2000151259 DE10051259A1 (en) 2000-10-16 2000-10-16 Non-human mammal with an altered PACAP type I receptor

Publications (2)

Publication Number Publication Date
WO2002033103A2 WO2002033103A2 (en) 2002-04-25
WO2002033103A3 true WO2002033103A3 (en) 2003-03-20

Family

ID=7659979

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2001/003957 Ceased WO2002033103A2 (en) 2000-10-16 2001-10-16 Non-human mammal with modified pacap type i receptor

Country Status (2)

Country Link
DE (1) DE10051259A1 (en)
WO (1) WO2002033103A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009033489A2 (en) * 2007-09-11 2009-03-19 Glostrup Hospital Selective pacl inhibitors for use in the treatment of migraine and headaches

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
DICKINSON T ET AL: "VIP and PACAP: very important in pain?", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 20, no. 8, 1 August 1999 (1999-08-01), pages 324 - 329, XP004173657, ISSN: 0165-6147 *
EKBLAD E ET AL: "Characterization of intestinal receptors for VIP and PACAP in rat and in PAC1 receptor knockout mouse.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 921, December 2000 (2000-12-01), Fourth International Symposium on VIP, PACAP, Glucagon, and Related Peptides;Elsinore, Denmark; September 02-04, 1999, related peptides: Fourth International Symposium. December, 2000 New York Academy, pages 137 - 147, XP001063211, ISBN: 1-57331-273-8 *
JAMEN FRANCOISE ET AL: "PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance.", JOURNAL OF CLINICAL INVESTIGATION, vol. 105, no. 9, May 2000 (2000-05-01), pages 1307 - 1315, XP002199544, ISSN: 0021-9738 *
JONGSMA, H. ET AL.,: "Markedly reduced chronic nociceptive response in mice lacking the PAC1 receptor", NEUROREPORT, vol. 12, no. 10, 20 July 2001 (2001-07-20), pages 2215 - 2219, XP001071197 *
KELLENDONK CHRISTOPH ET AL: "Inducible site-specific recombination in the brain.", JOURNAL OF MOLECULAR BIOLOGY, vol. 285, no. 1, 8 January 1999 (1999-01-08), pages 175 - 182, XP002199546, ISSN: 0022-2836 *
OTTO C ET AL: "ALTERED EMOTIONAL BEHAVIOR IN PACAP-TYPE-I-RECEPTOR-DEFICIENT MICE", MOLECULAR BRAIN RESEARCH, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1/2, no. 92, 15 August 2001 (2001-08-15), pages 78 - 84, XP001063307, ISSN: 0169-328X *
OTTO C ET AL: "PRESYNPATIC LOCALIZATION OF THE PACAP-TYPEI-RECEPTOR IN HIPPOCAMPAL AND CEREBELLAR MOSSY FIBRES", MOLECULAR BRAIN RESEARCH, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1/2, no. 66, 20 March 1999 (1999-03-20), pages 163 - 174, XP001057371, ISSN: 0169-328X *
OTTO CHRISTIANE ET AL: "Impairment of mossy fiber long-term potentiation and associative learning in pituitary adenylate cyclase activating polypeptide type I receptor-deficient mice.", JOURNAL OF NEUROSCIENCE, vol. 21, no. 15, 1 August 2001 (2001-08-01), pages 5520 - 5527, XP001057378, ISSN: 0270-6474 *
REICHARDT H M ET AL: "THE CRE/LOXP SYSTEM - A VERSATILE TOOL TO STUDY GLUCOCORTICOID SIGNALLING IN MICE", BIOCHEMICAL SOCIETY TRANSACTIONS, COLCHESTER, ESSEX, GB, vol. 27, 1999, pages 78 - 83, XP000960733, ISSN: 0300-5127 *
SAUVAGE MAGDALENA ET AL: "Mild deficits in mice lacking pituitary adenylate cyclase-activating polypeptide receptor type 1 (PAC1) performing on memory tasks.", MOLECULAR BRAIN RESEARCH, vol. 84, no. 1-2, 8 December 2000 (2000-12-08), pages 79 - 89, XP001079076, ISSN: 0169-328X *
TELEGEDY, G., KATALIN KOKAVSZKY: "The action of pituitary adenylate cyclase activating polypeptide (PACAP) on passive avoidance learning. The role of transmitters", BRAIN RESEARCH, vol. 874, 25 August 2000 (2000-08-25), pages 194 - 199, XP002199545 *
TSIEN JOE Z ET AL: "Subregion- and cell type-restricted gene knockout in mouse brain.", CELL, vol. 87, no. 7, 1996, pages 1317 - 1326, XP002199547, ISSN: 0092-8674 *
VAN GAALEN M M ET AL: "Increased anxiety-related behavior in mice lacking PACAP type I receptor.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 26, no. 1-2, 2000, 30th Annual Meeting of the Society of Neuroscience;New Orleans, LA, USA; November 04-09, 2000, pages Abstract No. - 761.18, XP002199548, ISSN: 0190-5295 *

Also Published As

Publication number Publication date
DE10051259A1 (en) 2002-05-08
WO2002033103A2 (en) 2002-04-25

Similar Documents

Publication Publication Date Title
WO2003022176A3 (en) Cardiac harness
WO1999033982A3 (en) Human genes and gene expression products i
WO2002070729A3 (en) Improved skin substitutes and uses thereof
WO2003020217A3 (en) Novel pyrazole analogs acting on cannabinoid receptors
NO993539L (en) New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g / ml, a process for preparing the formulation and its use
WO1999038972A9 (en) Human genes and gene expression products ii
WO1999058675A3 (en) Human genes and gene expression products v
BR0207325A (en) Therapeutic methods for diseases associated with decreased aop-1 or aop-1 gene expression
MXPA03002413A (en) B7-like molecules and uses thereof.
WO2002014500A3 (en) Human genes and gene expression products
WO2001066753A3 (en) Human genes and gene expression products
WO2001098268A3 (en) Piperidine amides as modulators of chemokine receptor activity
GR1002847B (en) Use of micropostol and/or micropostol acid for the preparation of a medicine for the therapeutic treatiment of problems related to the erection
ATE486168T1 (en) FIBER STRUCTURE AND METHOD FOR THE PRODUCTION THEREOF
ATE394379T1 (en) 4-ALKOXY-CYCLOHEXANE-1-AMINO-CARBONIC ACID ESTERS AND METHOD FOR THE PRODUCTION THEREOF
EP1168918A4 (en) VACCINE AND GENE THERAPY COMPOSITIONS, METHODS OF PRODUCING AND USES THEREOF
WO2001046394A3 (en) Mammalian protein phosphatases
PL350917A1 (en) C16 unsaturated fp-selective prostaglandins analogs
WO2002033103A3 (en) Non-human mammal with modified pacap type i receptor
AU2002259147A1 (en) Use of neurokinin receptor antagonists to treat androgen-dependent diseases
ATE313524T1 (en) 1,1- AND 1,2-DISUBSTITUTED CYCLOPROPANES, METHOD FOR THE PRODUCTION THEREOF AND THEIR PHARMACEUTICAL COMPOSITIONS
BR9811542A (en) Identification of human cell lines for the production of human proteins through endogenous gene activation
PT1141305E (en) CHIMERIC GENE FORMED BY DNA SEQUENCES THAT CODIFIES THE ANTIGENIC DETERMINANTS OF FOUR PROTEINS BY L. INFANTUM
WO2003076658A3 (en) A susceptibility gene for late-onset idiopathic parkinson's disease
WO2001064876A3 (en) Human schizophrenia gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase